PMID- 35200129
OWN - NLM
STAT- MEDLINE
DCOM- 20220510
LR  - 20220510
IS  - 0392-856X (Print)
IS  - 0392-856X (Linking)
VI  - 40
IP  - 4
DP  - 2022 May
TI  - Effect of numbers of metabolic syndrome components on mortality in patients with 
      antineutrophil cytoplasmic antibody-associated vasculitis with metabolic 
      syndrome.
PG  - 758-764
LID - 10.55563/clinexprheumatol/k4m3it [doi]
AB  - OBJECTIVES: This study investigated the effect of the number of metabolic 
      syndrome (MetS) components on all-cause mortality in patients with antineutrophil 
      cytoplasmic antibody-associated vasculitis (AAV) with MetS. METHODS: The medical 
      records of 93 AAV patients with MetS were retrospectively reviewed. MetS was 
      diagnosed when three or more the following MetS components for Asians were met: 
      (i) increased waist circumference; ii) high blood pressure; (iii) 
      hypertriglyceridaemia; (iv) low level of high-density lipoprotein 
      (HDL)-cholesterol; and (v) impaired fasting glucose (IFG) or type 2 diabetes 
      mellitus (T2DM). All-cause mortality was defined as death owing to any aetiology. 
      RESULTS: The median age was 61.4 years and 33 patients were men. Among 93 AAV 
      patients with MetS, as the number of MetS components increased, the cumulative 
      patient survival rate significantly decreased (p = 0.024). Compared to surviving 
      AAV patients with MetS, deceased AAV patients with MetS were older, had higher 
      Birmingham vasculitis activity score (BVAS) and Five-factor score (FFS), a lower 
      frequency of IFG or T2DM, and a higher number of MetS components. In the 
      multivariable Cox analysis, AAV patients with MetS who had all five MetS 
      components were approximately 62 times more susceptible to all-cause mortality 
      than those who had only three components. In terms of IFG or T2DM, patients with 
      only IFG exhibited a significantly lower cumulative patients' survival rate than 
      those without. CONCLUSIONS: The presence of many MetS components at the initial 
      diagnosis of AAV was an independent and significant predictor of all-cause 
      mortality in AAV patients with MetS.
FAU - Park, Pil Gyu
AU  - Park PG
AD  - Division of Rheumatology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Republic of Korea.
FAU - Pyo, Jung Yoon
AU  - Pyo JY
AD  - Division of Rheumatology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Republic of Korea.
FAU - Ahn, Sung Soo
AU  - Ahn SS
AD  - Division of Rheumatology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Republic of Korea.
FAU - Song, Jason Jungsik
AU  - Song JJ
AD  - Division of Rheumatology, Department of Internal Medicine, and Institute for 
      Immunology and Immunological Diseases, Yonsei University College of Medicine, 
      Seoul, Republic of Korea.
FAU - Park, Yong-Beom
AU  - Park YB
AD  - Division of Rheumatology, Department of Internal Medicine, and Institute for 
      Immunology and Immunological Diseases, Yonsei University College of Medicine, 
      Seoul, Republic of Korea.
FAU - Huh, Ji Hye
AU  - Huh JH
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Hallym 
      University Sacred Heart Hospital, Anyang, Republic of Korea.
FAU - Lee, Sang-Won
AU  - Lee SW
AD  - Division of Rheumatology, Department of Internal Medicine, and Institute for 
      Immunology and Immunological Diseases, Yonsei University College of Medicine, 
      Seoul, Republic of Korea. sangwonlee@yuhs.ac.
LA  - eng
PT  - Journal Article
DEP - 20220207
PL  - Italy
TA  - Clin Exp Rheumatol
JT  - Clinical and experimental rheumatology
JID - 8308521
RN  - 0 (Antibodies, Antineutrophil Cytoplasmic)
SB  - IM
MH  - *Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/diagnosis
MH  - Antibodies, Antineutrophil Cytoplasmic
MH  - *Diabetes Mellitus, Type 2
MH  - Female
MH  - Humans
MH  - Male
MH  - *Metabolic Syndrome
MH  - Middle Aged
MH  - Retrospective Studies
EDAT- 2022/02/25 06:00
MHDA- 2022/05/11 06:00
CRDT- 2022/02/24 12:19
PHST- 2021/11/13 00:00 [received]
PHST- 2022/01/10 00:00 [accepted]
PHST- 2022/02/25 06:00 [pubmed]
PHST- 2022/05/11 06:00 [medline]
PHST- 2022/02/24 12:19 [entrez]
AID - 18118 [pii]
AID - 10.55563/clinexprheumatol/k4m3it [doi]
PST - ppublish
SO  - Clin Exp Rheumatol. 2022 May;40(4):758-764. doi: 
      10.55563/clinexprheumatol/k4m3it. Epub 2022 Feb 7.